About CatalystPharma
CatalystPharma is a publicly listed company based in Coral Gables (United States) founded in 2002 by Hubert E Huckel and Patrick James Mcenany, and was acquired by Angelini Pharma in May 2026. Therapies for rare neuromuscular and neurological diseases are developed. The company has 181 employees. Its chief executive, as recorded, is Patrick James Mcenany. CatalystPharma offers products and services including Approved Products and Clinical Pipeline. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Catalyst Pharmaceuticals, Inc. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
CatalystPharma was founded in 2002 and is headquartered in Coral Gables, United States. Operations center on the development and commercialization of prescription drugs that target rare debilitating conditions, including Lambert-Eaton Myasthenic Syndrome, infantile spasms, and Tourettes disorder. Focus is placed on the pharmaceutical sector, with emphasis on neuromuscular and neurological diseases affecting limited patient populations.
- Headquarters Coral Gables, United States
- Employees 181
- Founders Hubert E Huckel, Patrick James Mcenany
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website catalystpharma.com
- Social LinkedIn X Facebook Instagram
- Acquired by Angelini Pharma (May 2026)
- Legal Name Catalyst Pharmaceuticals, Inc.
- Annual Revenue$491.73 M (USD)23.49as on Dec 31, 2024
- Net Profit$163.89 M (USD)129.5as on Dec 31, 2024
- EBITDA$233.18 M (USD)94.39as on Dec 31, 2024
- Latest Funding Round$37.38M (USD), Post-IPO
Feb 2015
- Investors
- Employee Count181
- Acquired byAngelini Pharma
(May 2026)
Products & Services of CatalystPharma
CatalystPharma offers a comprehensive portfolio of products and services, including Approved Products and Clinical Pipeline.
Medications for rare diseases like LEMS and DMD
Development of treatments for neurological conditions
Funding Insights of CatalystPharma
- Total Rounds 2
- Last Round Post-IPO — $37.38M
- First Round $15.1M
(Sep 2013)
All 2 funding rounds of CatalystPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2015 | $37.38M | Post-IPO | – | – | – |
| Sep 2013 | $15.1M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in CatalystPharma
CatalystPharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Angelini Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturer and developer of active ingredients, branded drugs, medical products and dietary supplements | 1919 | angelinipharma.com | Rome, Italy |
Investor details for CatalystPharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CatalystPharma
100 people are tracked at CatalystPharma (47 in leadership, 7 in board & advisors, 46 in team); the tracked headcount is 181.
| Name | Role | Group |
|---|---|---|
Hubert E Huckel | Co-Founder | Leadership |
Patrick James Mcenany | Co-Founder & CEO | Leadership |
Patrick J. McEnany | Co-Founder, Chairman, President & CEO | Leadership |
Steven R. Miller | Chief Operating Officer and Chief Scientific Officer | Leadership |
Alicia Grande | Vice President, Chief Financial Officer and Treasurer | Leadership |
Brian Elsbernd | Chief Legal and Compliance Officer | Leadership |
Susan Lehner | Senior Director, Firdapse Marketing | Leadership |
Michael Kalb | EVP & Chief Financial Officer | Leadership |
Alison Anderson | Medical Affairs Director, Neuromuscular | Leadership |
Preethi Sundaram | Chief Strategy Officer | Leadership |
Gary Ingenito | Chief Medical & Regulatory Officer | Leadership |
Jeff Del Carmen | Chief Commercial Officer | Leadership |
Jaymie Rodems | Director, Social Media & Digital Marketing | Leadership |
Stanley Iyadurai | Senior Vice President, Medical Affairs & Drug Discovery | Leadership |
Kevin Hurlahe | Area Business Director, Neuromuscular (lems) - Western US | Leadership |
Stephanie Paraboschi | Executive Director, Neurology | Leadership |
Mark Williams | Associate Director Quality Assurance | Leadership |
Mark Gelardi | Director Of Oncology | Leadership |
Patty Flores | Area Marketing Director,agamree-west | Leadership |
David Morrell | Senior Vice President Marketing | Leadership |
80 more people are available in the full profile.
Complete people profiles for CatalystPharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CatalystPharma
CatalystPharma is a publicly listed company on the NASDAQ with ticker symbol CPRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Nov 2006
- Listed onNASDAQ: CPRX
- Listed entityCatalyst Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS14888U1016
- Share price$31.15 (-0.05% on the day) · 2026-05-11
- Market capitalisation$3.81B
- Price to earnings18.5
- EPS (diluted, trailing year)$1.68
- Volume (last session)4,480,767
- Analyst consensusNeutral
Financials of CatalystPharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $491.7M | $163.9M | $233.2M |
| 2023 | $398.2M | $71.4M | $120.0M |
| 2022 | $214.2M | $83.1M | $103.3M |
| 2021 | $140.8M | $39.5M | $52.9M |
| 2020 | $119.1M | $75.0M | $42.2M |
Detailed financial statements for CatalystPharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of CatalystPharma
5 dated milestones of CatalystPharma across 24 years, from founding to its latest funding, stage changes and deals.
- Founded CatalystPharma is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $15.1M.
- Funding Latest funding round, Post-IPO, of $37.4M.
- Exit Acquired by Angelini Pharma.
Competitors of CatalystPharma
CatalystPharma has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of CatalystPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CatalystPharma
The website of CatalystPharma (catalystpharma.com) receives about 8.9K visits a month and ranks #2,466,713 among all websites worldwide, #3,383 in Biotechnology and Pharmaceuticals.
- Monthly visits8.9K
▲ 3.9% vs previous month
- Unique visitors3.8K
per month
- Global rank#2,466,713
among all websites
- Category rank#3,383
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.9
- Average visit31 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with CatalystPharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
llorenspharm.com | llorenspharm.com | 100% | – | ||
| noven.com | 99% | 7.2K | #3,107,578 | View details | |
| samedanltd.com | 90% | 4.2K | #4,232,761 | View details | |
lems.com | lems.com | 55% | – | ||
neuropathy.org | neuropathy.org | 48% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for CatalystPharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as CatalystPharma (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Catalystpharma
Complete news archive for CatalystPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CatalystPharma
CatalystPharma was founded in 2002 and raised its 1st funding round 11 years after it was founded.
CatalystPharma is headquartered in Coral Gables, United States. It is registered at Coral Gables, Florida, United States.
Patrick James Mcenany is the CEO of CatalystPharma, as recorded in our data. They have also founded this company.
CatalystPharma has 181 employees.
Annual revenue of CatalystPharma is $491.73M as on Dec 31, 2024.
CatalystPharma was founded in 2002 and is headquartered in Coral Gables, United States. Operations center on the development and commercialization of prescription drugs that target rare debilitating conditions, including Lambert-Eaton Myasthenic Syndrome, infantile spasms, and Tourettes disorder. Focus is placed on the pharmaceutical sector, with emphasis on neuromuscular and neurological diseases affecting limited patient populations.
CatalystPharma's top competitors include Moderna, Spark Therapeutics and BridgeBio.
CatalystPharma offers Approved Products and Clinical Pipeline.
Yes, CatalystPharma is publicly traded on NASDAQ under the ticker symbol CPRX.
CatalystPharma has 1 investor. Key investors include Angelini Pharma.
CatalystPharma operates through Catalyst Pharmaceuticals, Inc..
Yes. CatalystPharma was acquired by Angelini Pharma in May 2026.